Welcome to Vascular Pharmaceuticals
Vascular Pharmaceuticals (VPI) is a Delaware C-Corporation founded in 2005 with IP licensed from the University of North Carolina at Chapel Hill (UNC-CH) School of Medicine. The company’s lead product candidate, VPI-2690B, is a subcutaneously administered humanized mAb currently in Phase 2 clinical trials for the treatment of diabetic nephropathy. The company completed its Series A financing in September 2012 with Intersouth Partners and MPM Capital as co-lead investors. In parallel with the Series A closing, VPI entered into a transaction that provides Janssen with the right to acquire VPI on pre-negotiated terms after the completion of the Phase 2 trial.
VPI is enrolling a Phase 2 clinical trial testing VPI-2690B for the treatment of diabetic nephropathy. To learn more about the Phase 2 trial please click here ((link to http://www.vascularpharma.com/orchard/vpi-2690b))